Pacira Biosciences, Inc. · NASDAQ:PCRX
Pacira Biosciences — Q4 2023 Earnings Presentation
15 slides from Pacira Biosciences's earnings presentation, Jan 4, 2024
Slide 1: 4Q23 Earnings Presentation
4Q23 Earnings Presentation February 2024
Slide 2: Forward-looking statements and where to find additional information
Forward-looking statements and where to find additional information Any statements in this presentation about Pacira’s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intend
Slide 3: Advancing three key EXPAREL drivers in 2024
Advancing three key EXPAREL drivers in 2024 Launching EXPAREL Preparing for rollout Expanding access in two new lower of NOPAIN in 2025 through 340B extremity nerve pricing and new block indications GPO partnerships 3
Slide 4: Defining a thoughtful path for long-term growth | initial steps
Defining a thoughtful path for long-term growth | initial steps Reprioritizing investments to focus on Reallocating efforts NOPAIN-readiness and Reshaping our and resources from enhancing key executive team and rest of world and commercial capabilities launching searches for certain early-stage chie
Slide 5: Lower extremity nerve block launch further differentiates EXPAREL
Lower extremity nerve block launch further differentiates • Attractive value proposition as positive clinical EXPAREL is outcomes achieved with lower 10 mL dose • Extends reach within surgeries of the knee, lower leg, for use in lower extremity and foot and ankle procedures as an adductor – Strong p
Slide 6: Going to market with overwhelmingly positive body of data
Going to market with overwhelmingly positive body of data 4 61% D A Y S OF REDUCTION SIGNIFICANT IN O P I O I D CONSUMPTION PA I N C O N T R O L & 5X MORE L I K E L Y (p<0.01) TO BE OPIOID-FREE as a sciatic nerve block in the popliteal fossa (p<0.01) 23% REDUCTION IN O P I O I D CONSUMPTION as an ad
Slide 7: The road to NOPAIN
The road to NOPAIN A relentless multi-year initiative resulted in NOPAIN (Non-Opioids Prevent Addiction In the Nation) being signed into law 2018 2019 2020 2021 2022 EXPAREL becomes first Pacira takes legislative NOPAIN introduced as NOPAIN reintroduced Senate Finance Committee and only drug to brea
Slide 8: NOPAIN underscores leadership
NOPAIN underscores leadership Flaws of bundled payments Patient-centric legislative Opportunity to greatly for surgical procedures solution expand patient access • Impedes patient and provider • NOPAIN signed into law in Reimbursement pathway for access to best-practice pain management December 2022
Slide 9: Advancing pre-launch activities to ensure successful rollout of NOPAIN in 2025
Advancing pre-launch activities to ensure successful rollout of NOPAIN in 2025 AWARENESS EDUCATION ACTION Pharmacy C-suite Clinicians Payers Influencers Patients 9
Slide 10: Solidifying and growing our hospital customer base to expand access
Solidifying and growing our hospital customer base to expand access • Launching new GPO partnerships in 2024 ~25% of EXPAREL-relevant market procedures are in – Recently announced deal with Premier whose network of hospitals and health systems covers ~20% of EXPAREL-relevant market procedures inpati
Slide 11: Paragraph IV litigation illustrative timeline
Paragraph 4 litigation illustrative timeline FEBRUARY 6–11, 2024 MID-2024 2H2024 ± APPROXIMATELY 18 MONTHS Trial Duration Trial Opinion Pacira or eVenus Appeal process to pursue appellate review if warranted 11
Slide 12: Multiple layers of EXPAREL market exclusivity
Multiple layers of EXPAREL market exclusivity Patent Estate Regulatory Manufacturing 10 20+ FDA guidance on bioequivalence years of MVL Orange Book established rigorous hurdles; manufacturing Listed Patents generic liposomal bupivacaine must expertise 4 have equivalent multivesicular 6 product by ch
Slide 13: Strong fourth quarter financial performance
Strong fourth quarter financial performance • 4Q23 total revenue of $181M 2024 Financial Guidance Total Revenue $680-705M – EXPAREL net product sales of $144M Non-GAAP Gross Margin 74-76% – ZILRETTA net product sales of $29M Non-GAAP R&D $70-80M – iovera° net product sales of $6M Non-GAAP SG&A $245-
Slide 14: Positioned for sustainable success
Positioned for sustainable success Sharply focused on driving long-term growth 3 best-in-class products LENB launch a solid tailwind for EXPAREL Significant catalyst ahead in NOPAIN 2024 a key setup year to drive growth in 2025 and beyond Confident in strong and growing IP estate 14
Slide 15: Thank you
BIOSCIENCES , INC